Deep Track Capital LP Buys New Holdings in Silence Therapeutics plc (NASDAQ:SLN)

Deep Track Capital LP acquired a new stake in Silence Therapeutics plc (NASDAQ:SLNGet Rating) during the 4th quarter, Holdings Channel reports. The institutional investor acquired 950,798 shares of the company’s stock, valued at approximately $22,715,000. Silence Therapeutics accounts for 1.6% of Deep Track Capital LP’s portfolio, making the stock its 26th biggest position.

A number of other large investors also recently added to or reduced their stakes in SLN. JPMorgan Chase & Co. purchased a new position in Silence Therapeutics in the fourth quarter valued at about $157,000. Morgan Stanley raised its position in Silence Therapeutics by 11.0% in the third quarter. Morgan Stanley now owns 10,615 shares of the company’s stock valued at $218,000 after purchasing an additional 1,050 shares during the period. Bellevue Group AG purchased a new position in Silence Therapeutics in the fourth quarter valued at about $1,092,000. Blair William & Co. IL raised its position in Silence Therapeutics by 26.1% in the fourth quarter. Blair William & Co. IL now owns 56,026 shares of the company’s stock valued at $1,338,000 after purchasing an additional 11,582 shares during the period. Finally, Citigroup Inc. purchased a new position in Silence Therapeutics in the fourth quarter valued at about $1,365,000. 6.54% of the stock is currently owned by institutional investors.

Silence Therapeutics stock traded up $0.10 during midday trading on Thursday, hitting $10.45. The stock had a trading volume of 11,259 shares, compared to its average volume of 22,272. Silence Therapeutics plc has a 12 month low of $8.21 and a 12 month high of $35.00. The business has a fifty day moving average price of $14.64 and a 200 day moving average price of $19.25.

Silence Therapeutics (NASDAQ:SLNGet Rating) last announced its quarterly earnings data on Thursday, March 17th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.20. The firm had revenue of $4.60 million during the quarter, compared to the consensus estimate of $2.74 million. As a group, equities research analysts anticipate that Silence Therapeutics plc will post -1.95 earnings per share for the current year.

A number of brokerages have recently issued reports on SLN. Zacks Investment Research raised Silence Therapeutics from a “hold” rating to a “buy” rating and set a $9.75 target price on the stock in a research report on Wednesday. Chardan Capital began coverage on Silence Therapeutics in a research report on Thursday, March 31st. They set a “buy” rating and a $33.00 target price on the stock. Finally, HC Wainwright dropped their target price on Silence Therapeutics from $100.00 to $95.00 and set a “buy” rating on the stock in a research report on Tuesday, March 22nd.

Silence Therapeutics Company Profile (Get Rating)

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.

Further Reading

Want to see what other hedge funds are holding SLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Silence Therapeutics plc (NASDAQ:SLNGet Rating).

Institutional Ownership by Quarter for Silence Therapeutics (NASDAQ:SLN)

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.